CN111569044B - Composition containing porphyridium polypeptide and preparation method thereof - Google Patents
Composition containing porphyridium polypeptide and preparation method thereof Download PDFInfo
- Publication number
- CN111569044B CN111569044B CN202010481473.3A CN202010481473A CN111569044B CN 111569044 B CN111569044 B CN 111569044B CN 202010481473 A CN202010481473 A CN 202010481473A CN 111569044 B CN111569044 B CN 111569044B
- Authority
- CN
- China
- Prior art keywords
- porphyridium
- polypeptide
- parts
- peptide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 94
- 241000206618 Porphyridium Species 0.000 title claims abstract description 83
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 64
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title abstract description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229940010747 sodium hyaluronate Drugs 0.000 claims 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 229940099259 vaseline Drugs 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 18
- 206010052428 Wound Diseases 0.000 abstract description 17
- 239000006228 supernatant Substances 0.000 abstract description 8
- 230000029663 wound healing Effects 0.000 abstract description 8
- 239000011159 matrix material Substances 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 238000001962 electrophoresis Methods 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 5
- 238000000108 ultra-filtration Methods 0.000 abstract description 5
- 241000195493 Cryptophyta Species 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 4
- 230000008014 freezing Effects 0.000 abstract description 4
- 238000007710 freezing Methods 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 4
- 239000012528 membrane Substances 0.000 abstract description 4
- 239000012982 microporous membrane Substances 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract description 4
- 238000010257 thawing Methods 0.000 abstract description 4
- 208000014674 injury Diseases 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 13
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 5
- 229960002591 hydroxyproline Drugs 0.000 description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
- 206010039509 Scab Diseases 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- -1 trihydroxymethyl glycine Chemical compound 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- OTSVBELRDMSPKY-PCBIJLKTSA-N Ile-Phe-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OTSVBELRDMSPKY-PCBIJLKTSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- LTAWNJXSRUCFAN-UNQGMJICSA-N Phe-Thr-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LTAWNJXSRUCFAN-UNQGMJICSA-N 0.000 description 1
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 108060006184 phycobiliprotein Proteins 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a composition containing porphyridium polypeptide and a preparation method thereof, wherein the composition comprises the following effective components in parts by weight: 0.1-0.9 parts of porphyridium polypeptide; 99.1-99.9 parts of a matrix; the preparation method comprises the following steps: the acquisition step of porphyridium polypeptide: repeatedly freezing and thawing porphyridium, then carrying out ultrasonic crushing, centrifuging the obtained algae liquid, and taking supernatant; separating by vertical electrophoresis to obtain polypeptide with Kda below 5, i.e. porphyridium polypeptide; or homogenizing porphyridium, sterilizing, filtering, centrifuging, collecting supernatant, ultrafiltering with 0.001-0.1 μm microporous membrane ultrafiltration membrane system to obtain porphyridium polypeptide with molecular weight cutoff of 1 KDa; mixing: mixing porphyridium polypeptide and a matrix according to parts by weight; obtaining a composition comprising porphyridium polypeptides; the composition can promote wound healing, reduce wound opening time, and promote rehabilitation after body surface injury.
Description
Technical Field
The invention relates to a composition containing porphyridium polypeptide and a preparation method thereof, belonging to the technical field of biological pharmaceutical preparations.
Background
Porphyridium (Porphyridium) as a relatively primitive unicellular alga of Rhodophyta can produce a plurality of bioactive substances such as phycobiliprotein, polyunsaturated fatty acid and exopolysaccharide substances, and is mainly used as a bait for juvenile shrimps at present, but research shows that the Porphyridium has high medicinal value at present. In recent years, porphyridium preparation has special effect in preventing and treating cardiovascular and cerebrovascular diseases and resisting cancer. Research on porphyridium at the present stage mostly focuses on improving immunity, resisting cancer and resisting thrombus, but medicinal development on porphyridium is not carried out yet. With the development of molecular biology and separation and purification means, the active substances in porphyridium are to be further developed.
Disclosure of Invention
In order to overcome the defects of the prior art, the first object of the invention is to provide a composition containing porphyridium polypeptide, wherein the composition can promote wound healing, reduce wound opening time and help body surface recovery after damage.
The second purpose of the invention is to provide a preparation method of the composition containing the porphyridium polypeptide, the preparation method is used for separating specific polypeptide from the porphyridium, and the preparation efficiency and the repeatability are high.
The first purpose of the invention can be achieved by adopting the following technical scheme: a composition containing porphyridium polypeptide comprises the following effective components in parts by weight:
0.1-0.9 parts of porphyridium polypeptide;
99.1-99.9 parts of matrix.
Further, the porphyridium polypeptide includes at least one of a 6 peptide and a 17 peptide; the sequence of the 6 peptide is shown as SEQ ID NO.1, and the sequence of the 17 peptide is shown as SEQ ID NO. 2.
Further, porphyridium polypeptides include 6 and 17 peptides; the mass ratio of the 6 peptide to the 17 peptide is 1 (0.1-10).
Further, the mass ratio of 6 peptide to 17 peptide was 1:4.
Further, the composition comprises the following effective components in parts by weight:
further, the composition is a spreadable composition.
The second purpose of the invention can be achieved by adopting the following technical scheme: a method of making a composition comprising porphyridium polypeptides, comprising:
the acquisition of porphyridium polypeptide comprises the following steps: repeatedly freezing and thawing porphyridium, then carrying out ultrasonic crushing, centrifuging the obtained algae liquid, and taking supernatant; separating by vertical electrophoresis to obtain polypeptide below 5KDa, i.e. porphyridium polypeptide;
or homogenizing porphyridium, sterilizing, filtering, centrifuging, collecting supernatant, ultrafiltering with 0.001-0.1 μm microporous membrane ultrafiltration membrane system to obtain porphyridium polypeptide with molecular weight cutoff of 1 KDa;
mixing: the porphyridium polypeptide and the matrix are mixed according to the following weight portions: 0.1-0.9 part of porphyridium polypeptide and 99.1-99.9 parts of matrix are mixed; obtaining the composition containing the porphyridium polypeptide.
Further, in the step of obtaining porphyridium polypeptide, separation is performed by using a trihydroxymethyl glycine gel vertical electrophoresis.
Further, in the step of obtaining the porphyridium polypeptide, the operating pressure difference of ultrafiltration is 0.1-0.5MPa.
In the formula, the porphyridium polypeptide can repair body surface damage in a targeted manner, has no protein immunogenicity, avoids anaphylactic reaction of people with allergic constitution, can cause severe damage to skin soft tissue due to the fact that the body surface damage is damage caused by physical, biological, chemical and other factors and acts on the skin soft tissue of a human body, and the damaged skin can generate open wound according to the body surface to induce bacterial infection to cause septicemia.
Compared with the prior art, the invention has the beneficial effects that:
1. the composition containing the porphyridium polypeptide can promote wound healing, reduce the wound opening time, help the recovery after the body surface is damaged, and develop a new direction for the medical use of the porphyridium;
2. the preparation method of the composition containing the porphyridium polypeptide separates specific polypeptide from the porphyridium, and has high preparation efficiency and good repeatability.
Drawings
FIG. 1 is a graph of the wound healing rate of example 4;
FIG. 2 is a bar graph of scab removal time for example 4;
FIG. 3 is a bar graph of hydroxyproline content for example 4.
Detailed Description
The invention will be further described with reference to the accompanying drawings and the detailed description below:
the specific embodiment provides a composition containing porphyridium polypeptide, which comprises the following effective components in parts by weight:
wherein the porphyridium polypeptide comprises at least one of 6 peptide and 17 peptide; the sequence of the 6 peptide is shown as SEQ ID NO.1, and the sequence of the 17 peptide is shown as SEQ ID NO. 2; the mass ratio of the 6 peptide to the 17 peptide is 1 (0.1-10).
The preparation method of the composition containing the porphyridium polypeptide comprises the following steps:
the acquisition of porphyridium polypeptide comprises the following steps: repeatedly freezing and thawing porphyridium, then carrying out ultrasonic crushing, centrifuging the obtained algae liquid, and taking supernatant; separating polypeptide below 5KDa by vertical electrophoresis with trihydroxymethyl glycine (Tricine) gel to obtain porphyridium polypeptide;
or homogenizing porphyridium, sterilizing, filtering, centrifuging, collecting supernatant, ultrafiltering with 0.001-0.1 μm microporous membrane ultrafiltration membrane system with molecular weight cutoff of 1KDa and operation pressure difference of 0.1-0.5MPa to obtain porphyridium polypeptide;
mixing: mixing porphyridium polypeptide with a matrix; obtaining the composition containing the porphyridium polypeptide.
Example 1:
preparation of porphyridium polypeptide: adding sterile distilled water into porphyridium, repeatedly freezing and thawing (overnight at-20 deg.C and repeated at room temperature for 3 times), then ultrasonically crushing for 30min, stopping for 5min, and repeating for 5 times; centrifuging the obtained algae liquid and taking supernatant; separating with trihydroxymethyl glycine (Tricine) gel vertical electrophoresis, and collecting polypeptide band below 5KDa as porphyridium polypeptide; and cutting a target band, and detecting the cut target band, and analyzing by liquid chromatography-mass spectrometry to obtain two polypeptides: 6 peptide (720.87 Da) with sequence IFNLSK as shown in SEQ ID NO.1, 17 peptide (1862.18 Da) with sequence FTRPREVAAALPPPSPR as shown in SEQ ID NO. 2.
Example 2:
preparation of porphyridium polypeptide: adding 1-6 times of sterile water into porphyridium, homogenizing, sterilizing, filtering, centrifuging, collecting supernatant, ultrafiltering with an ultrafiltration membrane system with 0.001-0.1 μm microporous membrane, wherein the molecular weight cutoff is 1KDa, the operating pressure difference is 0.1-0.5MPa, and two polypeptides are obtained by liquid chromatography-mass spectrometry: peptide 6 (720.87 Da) with sequence IFNLSK as shown in SEQ ID NO.1, peptide 17 (18.18Da) with sequence FTRPREVAAALPPPSPR as shown in SEQ ID NO. 2.
Example 3:
preparation of the composition: the porphyridium polypeptide obtained in example 1 was mixed with the matrix in the parts by weight in table 1:
TABLE 1 compositions containing porphyridium polypeptides
Obtaining the composition containing the porphyridium polypeptide.
Example 4:
the composition obtained in example 3 was tested:
1) After SPF KM mice with the weight of 21.0 +/-1.8 g are selected and bred adaptively for one week, the mice are randomly divided into 3 groups, namely a control group, a porphyridium polypeptide group and a positive drug group. The mice are anesthetized with 350mg/kg chloral hydrate, after the back is unhaired and disinfected, the whole skin layer is cut on the back of the mice by using a circular medical puncher with the diameter of 8 mm to form a whole skin layer skin wound animal model, and the mice are raised in cages.
Porphyridium polypeptide group: preparing the mixture into paste according to the mass ratio of 2:1 in the embodiment 3 to water, and smearing the paste on a wound until the paste is fully smeared;
positive drug group: the Yunnan white drug powder is used as a positive control drug and is also smeared on wounds;
control group: no administration was given.
Taking a fixed-height photograph while dosing once every day, analyzing and calculating the wound healing rate by using Image J software, and calculating a formula: wound healing rate = (S) 0 －S N )/S 0 In the formula S 0 Represents the wound surface area of 0 day, S N Represents the wound area of N days, unit: square millimeters with N =0,1,3,4, …,14. The healing of the wound surfaces in each group is shown in fig. 1: the wound area of each group of mice gradually decreased with the time after injury prolonged, and soft scabs covered the wounds 1 day after model creation. The wound healing rate of the porphyridium polypeptide group is obviously higher than that of a control group from 1 day to 14 days after the modeling, the wound healing rate of the positive drug group starting from 2 days after the modeling is obviously higher than that of the control group, and the porphyridium polypeptide group has no obvious difference compared with the positive drug group from 1 to 7 days. But the healing rate of the porphyridium polypeptide group is higher than that of the positive medicament group at the 8 th day, the healing rate of the wound surfaces of each group at the 8 th day is that the porphyridium polypeptide group: (75.07 ± 3.53)%, positive drug group: (61.32 ± 3.01)% and control group: (42.35 ± 2.08)%; the healing rate of wound surfaces of each group on day 14, the percent of porphyridium polypeptide group (95.70 +/-0.80), the percent of positive drug group: (88.77 ± 4.50)% and control: (65.68. + -. 3.52)%.
FIG. 2 shows the scab removal times for each group, respectively: porphyridium polypeptide group: day (13.2 ± 0.6), positive drug group: day (14.8 ± 0.7), control group: (18.0. + -. 1.1) days. The porphyridium peptide group and the positive drug group have significantly reduced scab removal time compared with the control group.
2) The effect of the composition containing porphyridium polypeptides on the hydroxyproline content in wound tissue was examined, as shown in fig. 3. The hydroxyproline content in the wound surface tissues of all groups tends to increase along with the increase of time. On the 7 th day, the contents of wound hydroxyproline in the control group, the porphyridium peptide group and the positive medicament group are respectively (4025 +/-238) mu g/mg, (5018 +/-281) mu g/mg and (7862 +/-312) mu g/mg, and the contents of the porphyridium peptide group and the positive medicament group are obviously higher than those of the control group. On the 14 th day, the hydroxyproline content of the control group, the porphyridium peptide group and the positive drug group is (6873 +/-389) mu g/mg, (8341 +/-428) mu g/mg and (8512 +/-486) mu g/mg respectively, and the porphyridium peptide group and the positive drug group are obviously higher than the control group, which shows that the porphyridium peptide and the positive control drug Yunnan Baiyao have similar effects and can promote the deposition of collagen on wound surfaces.
Various other changes and modifications to the above-described embodiments and concepts will become apparent to those skilled in the art from the above description, and all such changes and modifications are intended to be included within the scope of the present invention as defined in the appended claims.
Sequence listing
<110> ocean medicine institute of Zhanjiang province of Guangdong
<120> a composition containing porphyridium polypeptide and preparation method thereof
<130> 2020
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 6
<212> PRT
<213> Porphyridium (Porphyridium)
<400> 1
Ile Phe Asn Leu Ser Lys
1 5
<210> 2
<211> 17
<212> PRT
<213> Porphyridium (Porphyridium)
<400> 2
Phe Thr Arg Pro Arg Glu Val Ala Ala Ala Leu Pro Pro Pro Ser Pro
1 5 10 15
Arg
Claims (2)
1. The composition containing porphyridium polypeptide is characterized by comprising the following effective components in parts by weight:
0.5 part of porphyridium polypeptide;
4.5 parts of vaseline;
3 parts of ascorbic acid;
2 parts of sodium hyaluronate;
90 parts of starch;
the porphyridium polypeptide comprises 6 peptide and 17 peptide; the sequence of the 6 peptide is shown as SEQ ID NO.1, and the sequence of the 17 peptide is shown as SEQ ID NO. 2; the mass ratio of the 6 peptide to the 17 peptide was 1:4.
2. The porphyridium-polypeptide-containing composition of claim 1, wherein the composition is a spread composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010481473.3A CN111569044B (en) | 2020-05-31 | 2020-05-31 | Composition containing porphyridium polypeptide and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010481473.3A CN111569044B (en) | 2020-05-31 | 2020-05-31 | Composition containing porphyridium polypeptide and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111569044A CN111569044A (en) | 2020-08-25 |
| CN111569044B true CN111569044B (en) | 2023-01-17 |
Family
ID=72114352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010481473.3A Active CN111569044B (en) | 2020-05-31 | 2020-05-31 | Composition containing porphyridium polypeptide and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111569044B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114225100A (en) * | 2021-12-22 | 2022-03-25 | 浙江清荣生物科技发展有限公司 | Porphyridium-based liquid dressing and preparation method thereof |
| CN115920001A (en) * | 2022-07-28 | 2023-04-07 | 广东医科大学 | Composition containing porphyridium polypeptide, preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8298548B2 (en) * | 2007-07-18 | 2012-10-30 | Solazyme, Inc. | Compositions for improving the health and appearance of skin |
| CN102961733A (en) * | 2012-11-16 | 2013-03-13 | 福建省水产研究所 | Application of seaweed polypeptide in preparing health-care product for reducing blood fat and blood sugar as well as beverage containing polypeptide for reducing blood fat and blood sugar |
| CN108785144A (en) * | 2018-09-04 | 2018-11-13 | 广东医科大学 | A kind of skin matrix and its application |
| CN110041413A (en) * | 2019-03-04 | 2019-07-23 | 齐鲁工业大学 | A kind of method of atomizing freeze drying machine assisted extraction phycoerythrin |
-
2020
- 2020-05-31 CN CN202010481473.3A patent/CN111569044B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111569044A (en) | 2020-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Collagen peptides derived from Sipunculus nudus accelerate wound healing | |
| KR20090120451A (en) | Natural (Telepeptide) Placenta Collagen Composition | |
| JP2020138956A (en) | Applications of pharmaceutical compositions containing fertilized fish egg extract, skin collagen growth promoters, medicated cosmetics, wound dressings and antioxidants, and fertilized fish egg extract | |
| HU217370B (en) | Bioactive products originated of peat and medical and cosmetical compositions containing them and method for preparing the medical compositions | |
| CN111569044B (en) | Composition containing porphyridium polypeptide and preparation method thereof | |
| KR101339423B1 (en) | cosmetic composition having collagen derived from fishes and manufacturing method thereof | |
| CN115340592A (en) | Active peptide and related application thereof | |
| CN114904046A (en) | Recombinant III-type humanized collagen composition and preparation method and application thereof | |
| CN110638836A (en) | Application of water-soluble pearl powder in promoting wound healing | |
| CN103520058A (en) | Silkworm chrysalis active polypeptide after-sun repairing gel and preparation method thereof | |
| KR101916759B1 (en) | The Method of High-yield and High-purity Manufacturing of Allo-collagen Composition Extracted From Human origin | |
| DE69528048T2 (en) | PEPTIDE OR PROTEIN CONTAINING HYALURONIC ACID WITH LOW MOLECULAR WEIGHT | |
| CN109320591A (en) | A kind of polypeptide OA-GL12 and its application | |
| WO2015012682A2 (en) | A method for extracting collagen from aquatic animals, collagen and products containing it | |
| CN108324926A (en) | The composition and application thereof of stem cell extract and antibacterial peptide | |
| JP2026501752A (en) | Compositions and uses for suppressing inflammatory responses and promoting angiogenesis and wound healing | |
| CN106046130B (en) | A kind of polypeptide and its application | |
| KR20120069221A (en) | Bee venom composition | |
| Varma et al. | Pharmaceutical & cosmetical application of keratin protein obtaining from biowaste-a review | |
| CN118684761A (en) | A recombinant humanized type III collagen and its encoding gene and application | |
| CN113134075B (en) | Antibacterial peptide cream and preparation method thereof | |
| Aditya | Stability test of glycosaminoglycan and achasin in snail (Achatina fullica) slime and its gel formulation | |
| CN115920001A (en) | Composition containing porphyridium polypeptide, preparation method and application thereof | |
| CN107904251A (en) | The preparation of TAT hEGF fusion proteins and its application in invisible face pack | |
| CN114621323B (en) | Polypeptide compound with skin repairing effect and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |